Yüklüyor......
BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
BRAF inhibitor (BRAFi) has been used for treatment of melanomas harboring V600E mutation. Despite a high initial response rate, resistance to BRAFi is inevitable. Here, we demonstrate that BRAFi-resistant (BR) melanomas are susceptible to arginine deprivation due to inability to initiate re-expressi...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4951241/ https://ncbi.nlm.nih.gov/pubmed/26771234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6882 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|